Trial Profile
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2022
Price :
$35
*
At a glance
- Drugs Cariprazine (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors Forest Laboratories
- 18 Oct 2022 Results of post hoc analysis of pooled data (NCT01396447, NCT02670538, NCT02670551) assessing which patients with bipolar depression could particularly benefit from 3 mg/d cariprazine presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
- 05 Oct 2021 Results assessing NCT00488618; NCT01058096; NCT01058668;NCT01396447; NCT02670538 and NCT02670551 assessing efficacy of cariprazine in manic, depressive, and cognitive symptoms in bipolar I disorder in light of its receptor profile, presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
- 01 Jun 2021 Results of pooled post hoc analysis assessing cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression published in the Journal of Affective Disorders